B-lymphocyte depletion with rituximab and β-cell function: two-year results - Wikidata - awgldk - TriplyDB

B-lymphocyte depletion with rituximab and β-cell function: two-year results

B-lymphocyte depletion with rituximab and β-cell function: two-year results

http://www.wikidata.org/entity/Q37504134

about

Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Altered Peripheral B-Lymphocyte Subsets in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice.Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.Immune therapy for treating type 1 diabetes: challenging existing paradigms.Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.Rituximab does not reset defective early B cell tolerance checkpoints Immune interventions to preserve β cell function in type 1 diabetes Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective Life and death of β cells in Type 1 diabetes: A comprehensive review.Potential beneficial effects of a gluten-free diet in newly diagnosed children with type 1 diabetes: a pilot study Experiments by nature: lessons on type 1 diabetes.Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.Islet inflammation in human type 1 diabetes mellitus.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus.Immunotherapies currently in development for the treatment of type 1 diabetes.Combination Immunotherapy for Type 1 Diabetes.B cell-targeted immunotherapy for type 1 diabetes: What can make it work?Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.Current and future efforts toward the prevention of type 1 diabetes.Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report Should There be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies.Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.Regulation of type 1 diabetes development and B-cell activation in nonobese diabetic mice by early life exposure to a diabetogenic environment.Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations.Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.Blockade of the activation of T cells around β-cell by the targeted CTLA-4 Ig at the surface of β-cell.Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy.Have we pushed the needle for treatment of Type 1 diabetes?Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes.B cells in type 1 diabetes mellitus and diabetic kidney disease.

P2860

Q26861561-B3743D62-AB85-4ECE-AC35-0179DEB400BF Q28081034-777ACD00-1138-446F-B54F-68DE7B6006A9 Q30716607-F6844AF4-F02B-42FC-B95C-FC574D351172 Q33836234-803A7938-7ED7-47AC-AA18-A4221D3860FC Q34380329-7BF7AD42-17A6-4453-A468-906F11875E0B Q35108159-BD2866D9-EA25-4647-8BAA-91A10407C1E3 Q35242386-744BE145-0490-4777-84FE-B5486B0232DD Q35242428-3351D89D-8D08-4ECE-B4EF-AB27D9937F89 Q36430775-27B8CA57-A35A-40BE-ABFC-F558E8AE3DF3 Q36520618-2BAC577C-19BA-45EE-A08C-BF4277665913 Q36749719-3E0507E9-D4ED-4BF6-B17B-E75266ED46DF Q36995568-9A2CBBB4-C63A-4C9E-A00B-57A6669102B5 Q37075420-F64C4707-3892-4300-A789-DEF12FFAB301 Q38172660-3BB2D073-9471-4894-9FEA-EE0DA80A4EC0 Q38262670-B6177A73-6DDC-4A3B-88F1-F6529D50398C Q38287783-8DA5D200-5A19-4717-9C87-A4CBA26DED6C Q38384138-6D544BEE-A0C9-46CC-A5CA-BCF878F33554 Q38387552-9C46A80C-A907-4902-A44D-6285906D5DC9 Q38585822-E0176B28-5776-47C9-AC29-DBF6032F9B37 Q38680333-C5FABD1E-7FE5-490F-9288-79709ED9AC34 Q38817783-3A88F4D6-4DD1-475B-8399-CC43F6626D8A Q38828063-E338B876-4D17-4383-AD3C-457DAD4EE668 Q38842306-34E137DC-B2B1-48F8-94A2-A82F23907052 Q38859330-827E0A4F-386F-48B2-A1D9-239A12B167AE Q38908327-A182F523-7987-4B79-BB25-81D666A47C3C Q38927961-7F7F9D07-A1DC-4C5C-9ECD-609429DAB122 Q39596760-85032CE8-AEBD-468B-8508-D98BFF53B309 Q40096435-01D3C109-D4FF-43EE-8418-C99D2631AA46 Q41070196-3DFDB794-E976-4670-B304-E7FF459B9DDE Q42320502-806EA2FC-3048-40C2-AD32-2CE10EDC2AB6 Q44700039-83D1E302-B8D9-4537-9AD2-B08A57E2277C Q45818945-E407CF09-9E8D-4C3A-84A6-790F003F2971 Q46453590-0C98F8F0-4FAA-43B7-993A-DE46D65B5D4F Q46486153-CE5416AA-E73C-47D7-9E95-A449D7717804 Q47375383-D4AC8497-2585-422E-AB63-7BFDB91E896E Q47577827-470253B1-AFE7-47AF-B48B-E1CF4BD4BD38 Q47621604-AF9DB0A0-6A3E-4DC2-8EDD-0E39C75FB8D6 Q47907621-2DD4AB71-7D4F-442B-AEFE-F5B3159C6342 Q49808758-E4146AAA-C165-4742-AD62-8237D99900A2 Q50077505-50C07BD5-7B3A-4B97-A28C-45C0321052F9

P2860

B-lymphocyte depletion with rituximab and β-cell function: two-year results

http://www.wikidata.org/entity/Q37504134

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

B-lymphocyte depletion with rituximab and β-cell function: two-year results

@en

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

@nl

type

label

B-lymphocyte depletion with rituximab and β-cell function: two-year results

@en

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

@nl

prefLabel

B-lymphocyte depletion with rituximab and β-cell function: two-year results

@en

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

@nl

P1433

Q37504134-CFD57F5E-047A-4F17-BD70-5495D8680D33

P1476

Q37504134-3A433CA6-79DA-45EB-97A6-9F55CB9CD22F

P2093

Q37504134-04F1557F-6CF1-4776-BA06-90C2043E41B5

Q37504134-310736E7-405C-409B-B9DE-AB565A09941D

Q37504134-35BB8376-5F31-4438-A823-7E7DC3DE138C

Q37504134-3D72B257-7368-41EC-A138-8A11DFE92119

Q37504134-5185DB24-F4BF-4560-8DB2-6EB86C7236D4

Q37504134-591238B1-7842-419A-9975-66F05BBE4CE9

Q37504134-6209B7D8-0A02-418F-8BE6-2C5B012B1560

Q37504134-677D52B4-1EF0-4576-B700-A2B4763E0716

Q37504134-6CD16405-15DD-44FC-BBAB-5939CA854836

Q37504134-7AE8441B-A2A1-4CF1-9190-B00510D3BCB9

P2860

Q37504134-0E8ADA68-EFEB-49E1-90F4-82073E4E25DF

Q37504134-16F59364-43CC-4797-AEC4-CFB5D122135D

Q37504134-297D4392-4F07-4BD9-930A-1267DE782777

Q37504134-31640F35-5040-4B1E-B68E-CAB8E849293F

Q37504134-3D3785E5-4576-46E9-BA70-BB836D5EFBA9

Q37504134-504C9FA0-DB1D-48D0-B492-78EF2ACF2EED

Q37504134-5C0AB2F7-230B-4645-ADDA-B6F81B3BB538

Q37504134-737105E1-DF17-4CDE-8A9F-A54E2F08D649

Q37504134-75170294-4E11-4406-A7F6-29CC99C0437E

Q37504134-7EFD8B47-13D0-4563-82E6-0DF6A717AA34

P304

Q37504134-1FFE518F-313E-4A0C-B90C-852BE29AD2F3

P31

Q37504134-2D1A625C-CEC3-475F-AF09-66F11D3C60DD

P356

Q37504134-DFBC08C9-A0A9-4CA2-A447-8E9B8D8FE0B0

P407

Q37504134-B3437F2A-2A9E-4020-98FB-6A83835E2805

P433

Q37504134-947FEAD9-FC76-4F53-A3DD-39DD24F2B191

P478

Q37504134-14E922FA-86F4-4B6E-BE41-C1A071D5C5A8

P50

Q37504134-48463715-F12D-4F4E-8F3B-870C365C8A96

P577

Q37504134-5051879F-4A8A-43BF-81D0-A084B9115E62

P5875

Q37504134-425244A4-F321-4D1D-95B1-B5F222AD04B9

P698

Q37504134-317335CE-AF36-408A-A47E-AFA1E073E460

P921

Q37504134-E984BC58-F39C-4440-8EC4-7CA7F7BE33C5

P932

Q37504134-0D5115DC-A6F2-470C-A91B-6222924027F1

P356

P1433

P1476

B-lymphocyte depletion with rituximab and β-cell function: two-year results

@en

P2093

Antoinette Moran

http://www.w3.org/2001/XMLSchema#string

Brian Bundy

http://www.w3.org/2001/XMLSchema#string

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Darrell M Wilson

http://www.w3.org/2001/XMLSchema#string

Desmond A Schatz

http://www.w3.org/2001/XMLSchema#string

Diane K Wherrett

http://www.w3.org/2001/XMLSchema#string

Dorothy J Becker

http://www.w3.org/2001/XMLSchema#string

Henry Rodriguez

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Krischer

http://www.w3.org/2001/XMLSchema#string

P2860

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Effect of rituximab on human in vivo antibody immune responses.

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

B cell-directed therapies in type 1 diabetes.

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

P304

453-459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0626

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044599

http://www.w3.org/2001/XMLSchema#string

P698

24026563

http://www.w3.org/2001/XMLSchema#string

P921

P932

3898764

http://www.w3.org/2001/XMLSchema#string